What is Pfizer's product — revenue?

Pfizer (PFE) reported product — revenue of $11.72B in Q1 2026.

How has Pfizer's product — revenue changed year-over-year?

Pfizer's product — revenue increased by 3.7% year-over-year, from $11.29B to $11.72B.

What is the long-term trend for Pfizer's product — revenue?

Over 4 years (2021 to 2025), Pfizer's product — revenue has grown at a 205.9% compound annual growth rate (CAGR), from $590M to $51.66B.

What does product — revenue mean?

This metric represents the total gross sales generated from a specific pharmaceutical product line or therapeutic category within the company's portfolio. It reflects the market demand, pricing power, and clinical adoption of individual drugs or vaccines. Tracking this allows investors to assess the revenue concentration and growth trajectory of key therapeutic franchises.

Pfizer PFE Product — Revenue

Other product segments

Eliquis

$2.17B+12.6%

Prevnar Family

$1.69B+1.8%

Vyndaqel family

$1.6B+7.8%

Ibrance

$1.01B+3.2%

All Other Hospital and Biosimilars

$953M—

All other Primary Care

$654M+7.4%

Padcev

$591M+38.7%

All other Specialty Care

$579M+19.1%

Xtandi

$444M-3.1%

Oncology Biosimilars

$409M+54.9%

Royalty

$396M+28.6%

All other Oncology

$376M-0.3%

Nurtec ODT/Vydura

$353M+42.3%

Lorbrena

$305M+37.4%

Pfizer CentreOne

$289M+5.9%

Comirnaty

$232M-58.9%

Paxlovid

$219M-69.9%

Inlyta

$214M-2.3%

Sulperazon (Outside the U.S. and Canada)

$199M+21.3%

Adcetris

$190M-12.8%

Inflectra

$182M—

Abrysvo

$180M+37.4%

Xeljanz

$180M+40.6%

Braftovi/Mektovi

$174M+27.9%

Zavicefta (Outside the U.S. and Canada)

$150M+11.1%

Enbrel (Outside the U.S. and Canada)

$138M-1.4%

Bosulif

$129M-14.6%

Octagam

$122M—

Tukysa

$122M+19.6%

Zithromax

$112M-29.1%

Orgovyx

$109M—

Genotropin

$93M—

FSME-IMMUN/TicoVac

$81M—

Elrexfio

$80M+33.3%

Cibinqo

$76M+31.0%

Talzenna

$50M+25.0%

Tivdak

$33M0.0%

Similar metrics at other companies

REGNProduct — Revenue

$1.53B+8.4%

LLYNet product revenue — Revenue

$18.45B+59.1%

GILDProduct sales — Total revenues

$6.95B+5.0%

BMYNet product sales — Total Revenues

$11.17B+2.6%

RYTMProduct revenue, net — Total revenues

$60.11M+59.4%

VRTXProduct revenues, net — Product revenues, net

$2.99B+8.2%

Other financials

Income statement

See full

Revenue$14.5B+5.4%

Gross profit$10.9B+0.3%

Net income$2.7B-9.4%

EPS (diluted)$0.47-9.6%

Balance sheet

See full

Cash & equivalents$1.8B+18.8%

Total debt$64.4B+4.9%

Total equity$90.1B-0.3%

Total assets$207.62B-0.2%

Cash flow

See full

Operating cash flow$2.6B+12.0%

CapEx$436.0M-22.7%

Free cash flow$2.2B+23.0%

Valuation

See full

Market cap$143.68B+11.1%

Enterprise value$206.35B+9.2%

P/E11.9×—

P/S2.3×+0.2×

Profitability

See full

Gross margin73.5%+1.2pp

Net margin15.7%—

FCF margin18%+8.8pp

Returns & leverage

See full

Return on equity10.6%—

Debt / equity0.7×0.0×

Current ratio1.2×0.0×

Where this comes from

Reported directly by Pfizer in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Pfizer’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pfizer's product — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Pfizer's product — revenue?: Pfizer (PFE) reported product — revenue of $11.72B in Q1 2026.
How has Pfizer's product — revenue changed year-over-year?: Pfizer's product — revenue increased by 3.7% year-over-year, from $11.29B to $11.72B.
What is the long-term trend for Pfizer's product — revenue?: Over 4 years (2021 to 2025), Pfizer's product — revenue has grown at a 205.9% compound annual growth rate (CAGR), from $590M to $51.66B.
What does product — revenue mean?: This metric represents the total gross sales generated from a specific pharmaceutical product line or therapeutic category within the company's portfolio. It reflects the market demand, pricing power, and clinical adoption of individual drugs or vaccines. Tracking this allows investors to assess the revenue concentration and growth trajectory of key therapeutic franchises.